Alligator Bioscience AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

26.10.18	Alligator Bioscience AB Interim Report January-September 2018 (PR Newswire)
05.10.18	Alligator Bioscience Receives Government Research Grant (PR Newswire)
05.10.18	Alligator Bioscience Receives Government Research Grant (PR Newswire)
28.09.18	New Preclinical Data Support Good Tolerability Properties for the 4-1BB Antibody ATOR-1017 (PR Newswire)
28.09.18	New Preclinical Data Support Good Tolerability Properties for the 4-1BB Antibody ATOR-1017 (PR Newswire)
30.08.18	Alligator Bioscience Presents at the 20th Annual Rodman & Renshaw Global Investment Conference (PR Newswire)
30.08.18	Alligator Bioscience Presents at the 20th Annual Rodman & Renshaw Global Investment Conference (PR Newswire)
19.07.18	Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody (PR Newswire)
19.07.18	Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody (PR Newswire)
12.07.18	Alligator Bioscience AB Interim Report January-June 2018 (PR Newswire)
12.07.18	Alligator Bioscience AB Interim Report January-June 2018 (PR Newswire)
21.06.18	Alligator Bioscience's ATOR-1017 Strongly Activates Both T cells and NK Cells, Important for the Effective Eradication of Tumor Cells (PR Newswire)
21.06.18	Alligator Bioscience's ATOR-1017 Strongly Activates Both T cells and NK Cells, Important for the Effective Eradication of Tumor Cells (PR Newswire)
29.05.18	Alligator Bioscience Capital Markets Day Today on May, 29 (PR Newswire)
29.05.18	Alligator Bioscience Capital Markets Day Today on May, 29 (PR Newswire)
16.05.18	Invitation to Alligator Bioscience Capital Markets Day in Stockholm on May 29, 2018 (PR Newswire)
08.05.18	New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Alligator Bioscience and Aptevo Therapeutics (PR Newswire)
03.05.18	Alligator Bioscience: ATOR-1017 Pre-clinical Data Support a Best-in-class 4-1BB Antibody Profile (PR Newswire)
03.05.18	Alligator Bioscience: ATOR-1017 Pre-clinical Data Support a Best-in-class 4-1BB Antibody Profile (PR Newswire)
26.04.18	Alligator Bioscience AB Interim Report January-March 2018 (PR Newswire)
26.04.18	Alligator Bioscience AB Interim Report January-March 2018 (PR Newswire)
17.04.18	Alligator Bioscience Presents ATOR-1015 Preclinical Data at the AACR Annual Meeting 2018 Confirming Localized Tumor Activation (PR Newswire)
17.04.18	Alligator Bioscience Presents ATOR-1015 Preclinical Data at the AACR Annual Meeting 2018 Confirming Localized Tumor Activation (PR Newswire)
05.04.18	Alligator Bioscience Presents at the H.C. Wainwright Annual Global Life Sciences Conference (PR Newswire)
05.04.18	Alligator Bioscience Presents at the H.C. Wainwright Annual Global Life Sciences Conference (PR Newswire)
22.03.18	Alligator Bioscience's Annual Report 2017 Published (PR Newswire)
16.02.18	Alligator Bioscience AB Full Year Report 2017 (PR Newswire)
16.02.18	Alligator Bioscience AB Full Year Report 2017 (PR Newswire)
25.01.18	Alligator Bioscience Contracts Theradex Oncology as Clinical CRO for the Upcoming ATOR-1015 Phase I Study (PR Newswire)
25.01.18	Alligator Bioscience Contracts Theradex Oncology as Clinical CRO for the Upcoming ATOR-1015 Phase I Study (PR Newswire)
18.01.18	Alligator Bioscience Appoints New VP Business Development (PR Newswire)
18.01.18	Alligator Bioscience Appoints New VP Business Development (PR Newswire)
04.01.18	Alligator Bioscience to Present at the 10th Annual Biotech Showcase Conference (PR Newswire)
04.01.18	Alligator Bioscience to Present at the 10th Annual Biotech Showcase Conference (PR Newswire)
03.01.18	Alligator Bioscience to Receive USD 6 Million Milestone Payment from Janssen Coupled to the Decision to Initiate Combination Trial with ADC-1013 (PR Newswire)
03.01.18	Alligator Bioscience to Receive USD 6 Million Milestone Payment from Janssen Coupled to the Decision to Initiate Combination Trial with ADC-1013 (PR Newswire)
04.12.17	Alligator Bioscience Expands Management Team (PR Newswire)
04.12.17	Alligator Bioscience Expands Management Team (PR Newswire)
21.11.17	Alligator Bioscience AB Presents at Redeye Life Science Seminar 24 November 2017 (PR Newswire)
21.11.17	Alligator Bioscience AB Presents at Redeye Life Science Seminar 24 November 2017 (PR Newswire)
07.11.17	Results From Alligator Bioscience's Clinical Phase I Study Support Further Clinical Development of ADC-1013 (PR Newswire)
07.11.17	Results From Alligator Bioscience's Clinical Phase I Study Support Further Clinical Development of ADC-1013 (PR Newswire)
25.10.17	Alligator Bioscience AB Interim Report January-September 2017 (PR Newswire)
25.10.17	Alligator Bioscience AB Interim Report January-September 2017 (PR Newswire)
24.10.17	Alligator Bioscience Aptevo Therapeutics: Tumor Antigen 5T4 Associated with Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527 (PR Newswire)
24.10.17	Alligator Bioscience Aptevo Therapeutics: Tumor Antigen 5T4 Associated with Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527 (PR Newswire)
21.09.17	Alligator Bioscience to Present ADC-1013 Intratumoral Clinical Phase I Study Results at SITC in November 2017 (PR Newswire)
21.09.17	Alligator Bioscience to Present ADC-1013 Intratumoral Clinical Phase I Study Results at SITC in November 2017 (PR Newswire)
13.09.17	Alligator Bioscience Signs Immunotherapy Research Collaboration Agreement for 4-1BB (PR Newswire)
13.09.17	Alligator Bioscience Signs Immunotherapy Research Collaboration Agreement for 4-1BB (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Alligator Bioscience AB

Aktien Top/Flop

Meistgelesene Nachrichten